Lesaffre, a prominent French company specialising in fermentation and microorganisms, has made a significant investment in Canadian firm CanBiocin, a leader in developing species-specific probiotics for companion animals and livestock. This partnership aims to enhance pet care solutions for a global audience.
The collaboration will unite the strengths of CanBiocin and Phileo, a division of Lesaffre, to create a comprehensive range of innovative probiotic solutions tailored to the specific needs of companion animals. By leveraging their combined expertise, both companies plan to develop unique, sustainable ingredients focused on animal health and wellness.
Brice-Audren Riché, CEO of Lesaffre, stated, “This strategic move perfectly aligns with Lesaffre’s unwavering commitment to customer proximity. Together with CanBiocin, with whom we share common values, we will expand our ability to provide comprehensive offerings and extensive portfolios that address our clients’ complete needs with end-to-end solutions.”
Manuel Maire, General Manager of Phileo by Lesaffre, added, “This investment marks an important step for Phileo by Lesaffre to expand our footprint in both companion animal food and supplements with a special focus on pets. CanBiocin’s expertise in novel probiotic strains perfectly complements our leadership in yeast probiotics and postbiotics, reinforcing our commitment to the companion animal care market.”
Dr. J.F. (Jake) Burlet, CEO of CanBiocin, emphasised the potential of the partnership: “Joining forces with Phileo will allow us to accelerate the development and commercialisation of our innovative products for the pet care and livestock sectors globally.”
This investment is expected to strengthen Phileo’s presence in the pet care market, especially following Lesaffre’s recent acquisition of a majority stake in Biorigin, a Brazilian natural ingredients specialist. Together, these companies aim to address the entire ecosystem of companion animal care with advanced, effective solutions.
